Nektar Therapeutics (NKTR)

NASDAQ: NKTR · IEX Real-Time Price · USD
2.61
+0.15 (6.10%)
At close: Jan 27, 2023, 4:00 PM
2.59
-0.02 (-0.77%)
After-hours: Jan 27, 2023, 5:59 PM EST
6.1%
Market Cap 490.56M
Revenue (ttm) 95.04M
Net Income (ttm) -454.16M
Shares Out 187.95M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,789,974
Open 2.42
Previous Close 2.46
Day's Range 2.41 - 2.63
52-Week Range 1.99 - 11.59
Beta 0.92
Analysts Sell
Price Target 4.50 (+72.41%)
Earnings Date Feb 27, 2023

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell l... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Howard Robin
Employees 740
Stock Exchange NASDAQ
Ticker Symbol NKTR
Full Company Profile

Financial Performance

In 2021, NKTR's revenue was $101.91 million, a decrease of -33.36% compared to the previous year's $152.92 million. Losses were -$523.84 million, 17.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for NKTR stock is "Sell." The 12-month stock price forecast is $4.5, which is an increase of 72.41% from the latest price.

Price Target
$4.5
(72.41% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan He...

3 weeks ago - PRNewsWire

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

NEW YORK , Dec. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) ...

1 month ago - PRNewsWire

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

-- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies -- -- Presents First Data for NKTR-255 in Combination with Daratumumab in Patients with Relapsed/Refractory M...

1 month ago - PRNewsWire

Nektar Therapeutics to Host Investor & Analyst Event on December 12th

SAN FRANCISCO , Dec. 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST. Nektar ma...

1 month ago - PRNewsWire

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

NKTR-288 upregulated MHC Class I and PD-L1 expression on tumors, enhancing anti-tumor activity when combined with anti-PD-1 or anti-PD-L1 antibodies SAN FRANCISCO , Nov. 10, 2022 /PRNewswire/ -- Nekta...

2 months ago - PRNewsWire

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy

-- Polymer-conjugated IL-15 (NKTR-255) induced CD8+ T cell and natural killer cell proliferation in vivo -- -- NKTR-255 enhanced the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model -...

2 months ago - PRNewsWire

Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates

Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter.

3 months ago - Zacks Investment Research

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 48.94% and 1.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Nektar Therapeutics Reports Third Quarter 2022 Financial Results

SAN FRANCISCO , Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in marketable secu...

3 months ago - PRNewsWire

Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Oct. 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the close of U.S.-b...

3 months ago - PRNewsWire

Form 8 (OPD) Nektar Therapeutics, Inc.

OPENING DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

3 months ago - GlobeNewsWire

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress

SAN FRANCISCO , Sept. 7, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as LY34...

5 months ago - PRNewsWire

Nektar.ai exits stealth mode to plug CRM data leakages

A lot of important data gets lost along the sales pipeline because sales teams use multiple tools, including email, Zoom and WhatsApp, to talk with buyers. Nektar.

5 months ago - TechCrunch

Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma

SAN FRANCISCO , Aug. 16, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society ...

5 months ago - PRNewsWire

Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates

Nektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased due to restructuring expenses of $106.0 million incurred during the quarter.

6 months ago - Zacks Investment Research

Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 15.84% and 7.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Nektar Therapeutics Reports Second Quarter 2022 Financial Results

SAN FRANCISCO , Aug. 4, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022. Cash and investments in marketable securiti...

6 months ago - PRNewsWire

Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-ba...

6 months ago - PRNewsWire

Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer

SAN FRANCISCO , July 1, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer.

7 months ago - PRNewsWire

Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track

Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.

9 months ago - Zacks Investment Research

Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Nektar Therapeutics Reports First Quarter 2022 Financial Results

SAN FRANCISCO , May 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022. Cash and investments in marketable securitie...

9 months ago - PRNewsWire

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

-  Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO -  Renowned oncology expert Dr. John Hayslip to further...

Other symbols: IMAB
9 months ago - PRNewsWire